Correction to: P0562 Comparative Efficacy and Safety of Upadacitinib Versus Oral Prednisolone for the Induction of Remission in Ulcerative Colitis: A Prospective, Multicenter, Open-label, Randomized Controlled Trial (PREDUPA Trial) Protocol and P0563 Mirikizumab Demonstrated Sustained and Durable Long-Term Efficacy and Favorable Safety in Week 52 Endoscopic Responders with Crohn’s disease: 3-year VIVID-2 Open-Label Extension Interim Results

Author unknown

Open source

DOI: 10.1093/ecco-jcc/jjag010
Published: 2026-07
Container: Journal of Crohn's and Colitis
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 58/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ecco-jcc/jjag010,
  title = {Correction to: P0562 Comparative Efficacy and Safety of Upadacitinib Versus Oral Prednisolone for the Induction of Remission in Ulcerative Colitis: A Prospective, Multicenter, Open-label, Randomized Controlled Trial (PREDUPA Trial) Protocol and P0563 Mirikizumab Demonstrated Sustained and Durable Long-Term Efficacy and Favorable Safety in Week 52 Endoscopic Responders with Crohn’s disease: 3-year VIVID-2 Open-Label Extension Interim Results},
  year = {2026},
  journal = {Journal of Crohn's and Colitis},
  doi = {10.1093/ecco-jcc/jjag010},
  url = {https://doi.org/10.1093/ecco-jcc/jjag010}
}

RIS

TY  - JOUR
TI  - Correction to: P0562 Comparative Efficacy and Safety of Upadacitinib Versus Oral Prednisolone for the Induction of Remission in Ulcerative Colitis: A Prospective, Multicenter, Open-label, Randomized Controlled Trial (PREDUPA Trial) Protocol and P0563 Mirikizumab Demonstrated Sustained and Durable Long-Term Efficacy and Favorable Safety in Week 52 Endoscopic Responders with Crohn’s disease: 3-year VIVID-2 Open-Label Extension Interim Results
PY  - 2026
JO  - Journal of Crohn's and Colitis
DO  - 10.1093/ecco-jcc/jjag010
UR  - https://doi.org/10.1093/ecco-jcc/jjag010
ER  -

APA

Correction to: P0562 Comparative Efficacy and Safety of Upadacitinib Versus Oral Prednisolone for the Induction of Remission in Ulcerative Colitis: A Prospective, Multicenter, Open-label, Randomized Controlled Trial (PREDUPA Trial) Protocol and P0563 Mirikizumab Demonstrated Sustained and Durable Long-Term Efficacy and Favorable Safety in Week 52 Endoscopic Responders with Crohn’s disease: 3-year VIVID-2 Open-Label Extension Interim Results. (2026). Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjag010

Source records

crossref · retrieved 2026-09-25T18:20:39.017Z